The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The use of long-acting beta-agonists (LABAs) in the treatment of persistent asthma has become one of the most controversial issues of respiratory disease management during this decade. Both salmeterol and formoterol have been shown in numerous clinical trials of asthma to dramatically improve pulmonary...
This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant...
The FDA is investigating Merck's Singulair for a possible link to suicidal thought and action. With over 28 million prescriptions last year and a 12 year record of safety in children and adults, the evidence must be evaluated closely before coming to any conclusion. Of note antihistamines, including...
The continued trend of concierge medicine will serve to further segregate and fragement our over burdened health care system. It remains to be seen then long effect of this practice model.
Not surprisingly the BLues are cutting reimbursement to physicians yet their rates continue to rise and their employee compensation continues to rise. It is time for employeers to demand that the highly paid executives of the Blues justify their excessive salaries and efficiencies of the Blues be fixed....
Medimmunes novel mAb to the Il5 receptor represents a novel way to decrease eosinophils. While this represents a potentially important therapeutic modality in asthma mangement, previous attempts with mepolizumab ( anti IL 5 ) proved disaapointing. Mepolizumab like medimmune's new agent was able to decrease...
Symbicort is AstraZeneca's answer to Advair, presently the number one combination ICS/LABA in the U.S. for treating moderate to severe asthma. Symbicort will not, however, have an indication for quick relief of bronchospasm as it does in many European countries. Nevertheless, Symbicort appears to be...
Yet another antihistamine in a saturated market with less expensive alternatives. Antihistamines are not the drug of choice for significant allergic rhinitis
The black box warning is a real concern to physicians who prescribe Xolair and patients who are taking it. It highlights a risk that has always been there but is apparently more common than previously thought.